Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer

NCT01996306 is registered in ClinicalTrials.gov with Epidemiological and Clinical Research Information Network as lead sponsor.

NCT NCT01996306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01996306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer
Lead sponsor
Epidemiological and Clinical Research Information Network
Phase
Phase 3
Overall status
Completed
Start date
December 2, 2013
Completion date
June 30, 2018
Enrollment
650 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, digestive system neoplasms, gastrointestinal neoplasms, intestinal neoplasms, neoplasm metastasis